Committee releases new guideline for management of high blood pressure

The 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults contains nine recommendations for health care providers.

A new guideline developed by evidence gathered from randomized clinical trials for the management of high blood pressure contains nine recommendations and a treatment algorithm to help doctors treat patients with hypertension. The guideline was published online today by the Journal of the American Medical Association with the goal of providing health care providers with recommendations for the pharmacologic management of hypertension.

A panel appointed to the Eighth Joint National Committee (JNC 8), co-chaired by Suzanne Oparil, M.D., University of Alabama at Birmingham professor of Medicine and director of the vascular biology and hypertensive program in UAB’s School of Medicine, used rigorous evidence-based methods to develop recommendations for blood pressure treatment based on a systemic review of the literature. The report, titled “2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults,” was developed in an effort to assure patients that blood pressure treatment will reduce their disease burden and to give clinicians guidance on hypertension management using the best scientific evidence.

“Hypertension is the most common condition seen in primary care and leads to heart attack, stroke, kidney failure and death if not detected early and treated appropriately,” Oparil said. “This report takes a rigorous, evidence-based approach to recommend treatment thresholds, goals and medications in the management of hypertension in adults. In utilizing randomized clinical trials, we used the highest level of medical evidence that one can have, and this is a process that is endorsed by The Institute of Medicine of the National Academy of Sciences.”

The guideline addresses three questions related to high blood pressure management:

In adults with hypertension, does treatment with antihypertensive pharmacologic therapy to a specified blood pressure goal lead to improvements in health outcomes?

In adults with hypertension, do various antihypertensive drugs or drug classes differ in comparative benefits and harms on specific health outcomes?

The nine recommendations in the guideline address those three questions.

Oparil says there are important differences from the past versions of the guideline. The new guideline, for example, focused on the three critical questions above, reviewed pertinent evidence from randomized clinical trials with important clinical outcomes, and used the evidence to develop easily understandable clinical recommendations. The guideline also sought to establish similar treatment goals for all hypertensive populations, except when evidence supports different goals for a particular subpopulation.

“There is very clear evidence that treating high blood pressure in people 60 and older to a goal of <150/<90 reduces stroke, heart attacks and heart disease,” Oparil said. “There is no evidence that lowering blood pressure further offers additional health benefits, and, further, taking unnecessary medication may increase the burdens on patients, resulting in additional time in the doctor’s office and expensive testing.”

The panel recommended that the blood pressure goal for people under age 60 should be <140/<90, based on expert opinion.

The report also addresses the treatment of blood pressure in those with kidney disease or diabetes. The panel adopted the blood pressure goal of <140/<90 for those groups, based on expert opinion.

“The potential benefits of a healthy diet, weight control and regular exercise for all persons with hypertension cannot be overemphasized,” Oparil said. “These lifestyle treatments have the potential to improve blood pressure and even reduce medication needs.”

When medication is needed to treat patients, the panel says those with the highest benefit based on the clinical trial evidence are diuretics, calcium channel blockers (CCBs), angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).

“All of those have shown to be useful in the general patient with high blood pressure,” Oparil said. “For nonblack patients, all of those classes seem to be equal. For blacks, CCBs and thiazide-type diuretics seem to be better than the ARBs or ACEIs in first-line treatment. Once that’s been accomplished, add drugs from other classes with complementary mechanisms of action.”

Oparil adds that ACE inhibitors and ARBs should not be used together. They have the same general mechanism of action, give no added benefit when combined and may have adverse effects when used together. Beta blockers are second-tier options.

Smita Bhatia, M.D., M.P.H., director of UAB's new Institute for Cancer Outcomes and Survivorship, explains how cancer treatments can lead to chronic health conditions in later life — and how "survivorship clinics" will help.

Naloxone kits have prevented more than 10,000 deaths from opioid overdose since local distribution programs began in 1996. Now, as deaths from opioid overdose reach an all-time high in the United States, a crowdfunded project from UAB researchers aims to put naloxone in the hands of those at highest risk.

About half of American hospitals have some form of arts programming, usually art or music therapy. Now a growing number of medical centers — UAB Hospital is the first in Alabama — are implementing the more comprehensive AIM model.